Pediatric Bone Marrow Transplant for Acute Lymphoblastic Leukemia (ALL) at Sheba Hospital- JCI accreditated and Top-10 Hospitals 2025 by Newsweek
このパッケージに含まれるもの
医療処置
- 生化学的血液検査
- 血液内科相談
- 血液検査
- 骨髄生検
- オンコヘマトロジー相談
- 白血病の包括的検査
- 骨髄細胞遺伝学的検査
- 骨髄穿刺検査および細胞遺伝学分析
- 骨髄移植術
- 自家骨髄移植術
- 非血縁者間同種骨髄移植術
- 同種骨髄移植術
- 栄養士による1日3食
- 24時間看護サービス
- 心電図(ECG)
- 血液検査
- 胸部X線
- HIV抗体検査
- B型肝炎コア抗体検査
- 抗HCV抗体検査
- 心エコー図検査
- 全血球計算(CBC)
- 生化学血液検査
- PET/CT
- 免疫専門医への相談
- 循環器科医への相談
- 小児血液専門医との相談
- 小児科医との相談
- 腫瘍血液専門医との診察
- 頭部MRI
- 生検
- 腫瘍マーカーおよび蛋白分画を含む全血球算定
期間
- 30 日 病院で
宿泊
入院
交通
空港-クリニック-空港間の送迎
追加情報
Pediatric Bone Marrow Transplant for Acute Lymphoblastic Leukemia (ALL)
Sheba Medical Center – Advanced, Personalized Care for Children
At Sheba Medical Center, we understand how overwhelming a diagnosis of Acute Lymphoblastic Leukemia (ALL) can be for both children and their families. Our mission is to provide not only the most advanced medical care available, but also reassurance, clarity, and compassionate support throughout every stage of treatment.
As a global leader in pediatric hemato-oncology, Sheba offers cutting-edge bone marrow transplantation (BMT) for children with ALL particularly in cases where the disease is high-risk, relapsed, or resistant to standard therapies.
When is a Bone Marrow Transplant Needed in ALL?
While many children with ALL respond very well to chemotherapy, some require a more intensive approach to achieve a lasting cure.
A bone marrow transplant may be recommended when:
The leukemia has relapsed
The disease is resistant to treatment
There are high-risk genetic features
A deeper, more durable remission is needed
In these situations, BMT replaces the diseased bone marrow with healthy stem cells helping rebuild a new immune system capable of eliminating leukemia cells.
A Personalized Treatment Strategy
Every child’s condition is unique. At Sheba, treatment decisions are made by a dedicated team of pediatric leukemia and transplant specialists who carefully tailor each plan.
Whenever possible, a matched sibling donor is used.
If no sibling match is available, we actively secure the most suitable donor using advanced matching technologies and global registries, including:
Matched unrelated donors from international donor programs
Haploidentical (half-matched) family donors, such as parents
Cord blood transplantation
Our state-of-the-art HLA and molecular laboratories ensure highly accurate matching, improving safety and transplant success.
Advanced Therapies for Better Outcomes
Sheba is at the forefront of innovation in pediatric ALL treatment, combining transplantation with the latest breakthroughs:
CAR-T cell therapy, often used before transplant in relapsed or refractory ALL to achieve remission
T-cell depletion and CD34+ selection reducing complications such as graft-versus-host disease
Access to international clinical trials and novel therapies
This integrated approach allows us to treat even the most complex cases successfully.
Leading Results in Pediatric ALL
Sheba’s outcomes for pediatric ALL are among the best internationally:
~70–85% success rates in children undergoing transplant in remission
Improved outcomes in relapsed cases through CAR-T integration
Strong long-term survival and quality of life
Our continuous research and clinical expertise ensure that every child benefits from the most advanced care available today.
Care That Supports the Whole Family
At Sheba, we treat more than the disease - we care for the child and their family as a whole. Children are treated in specialized, highly protected environments with advanced infection control, while families receive ongoing support, guidance, and clear communication.
Our team stays closely involved throughout the entire journey, ensuring each child is supported medically and emotionally on the path to recovery.
Why Families Choose Sheba for ALL Treatment
Global leader in pediatric leukemia and bone marrow transplantation
Expertise in high-risk and relapsed ALL
Ability to secure optimal donors even without a family match
Integration of CAR-T therapy and advanced cellular treatments
Multidisciplinary, patient-centered approach
Dedicated services for international families
A Message of Hope
For children facing Acute Lymphoblastic Leukemia, a bone marrow transplant can offer a real chance for cure. At Sheba Medical Center, we combine advanced science with compassionate care helping children overcome leukemia and move forward toward a healthy, hopeful future.
24時間年中無休Bookimedサポート
- 専任医療コーディネーター
- 医療旅行手配 — 特別パートナー価格での航空券・ホテル予約
- 医療旅行中の患者擁護
プログラム料金
このパッケージに含まれないもの
医師
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
調子はいかがですか?
クリニックについて
シェバ医療センターはイスラエルおよび世界有数の病院の一つです。 ニューズウィーク・インターナショナル誌は、Sheba Hospitalを2020年の世界トップ10病院にランク付けしました。同病院は1,990の専門分野をカバーしており、毎年世界中から1,500,000人を超える患者がシェバ病院を受診しています。
支払い・特典
当社サービスへのお支払いはありません
クリニックで直接またはその公式銀行口座にお支払いいただきます。
一部のクリニックでは保証金が必要な場合があります。
分割払いオプションでお支払いを分散してください。
Bookimedにお友達を紹介して報酬を獲得してください。